KSI-301: an investigational anti-VEGF biopolymer conjugate for retinal diseases

ABSTRACT

Introduction

KSI-301 is an intravitreal anti-vascular endothelial growth factor (VEGF) agent in clinical trials for the treatment of neovascular age-related macular degeneration (nAMD), diabetic retinopathy, diabetic macular edema (DME), and retinal vein occlusion (RVO). Its antibody-biopolymer conjugate structure is designed to decrease clearance from the eye and increase the duration of the effect.

Areas covered

This article briefly discusses the impact and mechanisms of nAMD, DME, and RVO and evaluates currently approved anti-VEGF therapies. It progresses to examine a new agent, KSI-301 and the results from numerous clinical trials in these disease areas.

Expert opinion

Despite varied results in the phase 2b/3 study for nAMD, there is potential for KSI-301 to serve as a durable therapy for VEGF-mediated retinal disorders. Ongoing phase 3 trials for nAMD, DME, and RVO will provide additional evidence on its efficacy, duration, and safety profiles.

KEYWORDS:

• KSI-301
• anti-VEGF
• intravitreal injection
• angiogenesis
• neovascular age-related macular degeneration
• diabetic retinopathy
• diabetic macular edema
• retinal vein occlusion

Disclosure statement

No potential conflict of interest was reported by the author(s)

Additional information

Funding

This paper was not funded.